Table 3.

Demographics, clinical–pathological characteristics, treatment, oncologic outcomes of the EC patients who underwent FPT.

Patients (No.)	Age at diagnosis (years)	BMI (kg/m2)	Pre-diagnosis GxPx	Pathology	Diagnostic method	Treatment, mg/day		Treatment duration, months
1	31	21.9	G0P0	G1 EAC	D&C	MA, 160 + MPA, 250		3 +3
2	35	20.4	G2P1	G1 EAC	Hysteroscopy	MA, 160		3
3	23	20.7	G0P0	G1 EAC	D&C	MA, 160		6
4	29	18.4	G1P0	G1 EAC	D&C	MA, 160		3
5	28	30.8	G0P0	G1 EAC	Hysteroscopy	MA, 160 + LNG-IUS		6 + 5
6	33	37.6	G0P0	G1 EAC	D&C	MA, 160 + LNG-IUS		6
7	26	26.6	G0P0	G1 EAC	Hysteroscopy	MPA, 250 + LNG-IUS		10
8	34	39.4	G2P0	G1 EAC	Hysteroscopy	MPA, 500		24
9	29	30.7	G0P0	G1 EAC	Hysteroscopy	LNG-IUS		12
10	23	24.8	G0P0	G1 EAC	Hysteroscopy	LNG-IUS		11
11	29	18.6	G0P0	G1 EAC	Hysteroscopy	MA, 160		3
12	31	20.4	G0P0	G1 EAC	Hysteroscopy	MPA, 250 + LNG-IUS		4
13	37	20.3	G0P0	G1 EAC	Hysteroscopy	MA, 160 + GnRH-A (i.m)		1month + 4 times
Patients (No.)	Follow-up duration, months	Oncologic outcome at 6 months	Final diagnosis	Recurrence (months)	Second cancer (months)	Hysterectomy	Current status	GxPx at the end of the treatment
1	138	CR	Normal	–	–	No	NED	G0P0
2	120	CR	Normal	–	–	No	NED	G2P1
3	123	CR	Normal	107	Ovarian cancer (107)	Yes	AWD	G0P0
4	84	CR	Normal	–	–	Yes	NED	G1P0
5	60	Progression1	EAC	–	–	Yes	NED	G0P0
6	48	CR	Normal	–	–	No	NED	G0P0
7	46	CR	Normal	–	–	No	NED	G0P0
8	27	PR	Normal	–	–	No	NED	G2P0
9	15	CR	Normal	–	–	No	NED	G0P0
10	11	CR	Normal	–	–	No	NED	G0P0
11	12	Persistent	EAC	–	–	Yes	NED	G0P0
12	15	CR	Normal	–	–	No	NED	G0P0
13	13	Persistent	EAC	–	–	Yes	NED	G0P0

¹Definitive surgery at 5 months.

BMI, body mass index; G, gravida; P, para; G1, Grade 1; D&C, dilation and curettage; EAC, endometrioid adenocarcinoma; MA, megestrol acetate; MPA, medroxyprogesterone acetate; LNG-IUS, Levonorgestrel-releasing intrauterine system; GnRH-A, Gonadotropin-releasing hormone agonist; i.m, intramuscular injection; CR, complete response; AWD, alive with disease; NED, no evidence of disease.